Research progress on hypercoagulable state in patients with acromegaly

Abstract

Abstract: Acromegaly is associated with systemic complications due to excess serum growth hormone, including cardiovascular diseases, endocrine and metabolic diseases, bone diseases and respiratory diseases. In addition, abnormalities of haemostatic function in patients with acromegaly have been described by several studies recently, including the alterations in coagulation, anticoagulation, fibrinolytic system and platelet function, presenting a potential of hyper-coagulation. Significantly elevated fibrinogen levels, reduced levels of protein C and protein S, and enhanced platelet activity were observed in patients with acromegaly. Some of these abnormalities are reversible after treatment like surgery or medication.

Key words: acromegaly, hypercoagulable state, fibrinogen, protein C, platelet

CLC Number:

R584.1

MA Li-yuan, GUO Xiao-peng, XING Bing. Research progress on hypercoagulable state in patients with acromegaly[J]. Basic & Clinical Medicine, 2020, 40(10): 1426-1430.

References

[1] Vilar L, Vilar CF, Lyra R, et al. Acromegaly: clinical features at diagnosis[J]. Pituitary, 2017,20: 22-32.
[2] Gadelha MR, Kasuki L, Lim DST, et al. Systemic complications of acromegaly and the impact of the current treatment landscape: an update[J]. Endocr Rev, 2019,40: 268-332.
[3] Dal J, Feldt-Rasmussen U, Andersen M, et al. Acrome-galy incidence, prevalence, complications and long-term prognosis: a nationwide cohort study[J]. Eur J Endocrinol, 2016,175: 181-190.
[4] Elarabi AM, Mosleh E, Alamlih LI, et al. Massive pulmonary embolism as the initial presentation of acromegaly: is acromegaly a hypercoagulable condition?[J]. Am J Case Rep, 2018,19: 1541-1545.
[5] Delaroudis SP, Efstathiadou ZA, Koukoulis GN, et al. Amelioration of cardiovascular risk factors with partial biochemical control of acromegaly[J]. Clin Endocrinol (Oxf), 2008,69: 279-284.
[6] Demirpence M, Yasar HY, Colak A, et al. Mean platelet volume and platelet function analysis in acromegalic patients before and after treatment[J]. Acta Endocrinol (Buchar), 2016,12: 401-406.
[7] Erem C, Nuhoglu I, Kocak M, et al. Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI[J]. Endocrine, 2008,33: 270-276.
[8] Landin-Wilhelmsen K, Lundberg PA, Lappas G, et al. Insulin-like growth factor I levels in healthy adults[J]. Horm Res, 2004,62 Suppl 1: 8-16.
[9] Vilar L, Valenzuela A, Ribeiro-Oliveira A, et al. Multiple facets in the control of acromegaly[J]. Pituitary, 2014,17 Suppl 1: S11-17.
[10] Colak A, Yilmaz H, Temel Y, et al. Coagulation parameters and platelet function analysis in patients with acromegaly[J]. J Endocrinol Invest, 2016,39: 97-101.
[11] Amado A, Araujo F, Carvalho D. Cardiovascular risk factors in acromegaly: what's the impact of disease control?[J]. Exp Clin Endocrinol Diabetes, 2018,126: 505-512.
[12] Sartorio A, Cattaneo M, Bucciarelli P, et al. Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly[J]. Exp Clin Endocrinol Diabetes, 2000,108: 486-492.
[13] Wildbrett J, Hanefeld M, Fucker K, et al. Anomalies of lipoprotein pattern and fibrinolysis in acromegalic patients: relation to growth hormone levels and insulin-like growth factor I[J]. Exp Clin Endocrinol Diabetes, 1997,105: 331-335.
[14] Olie RH, van der Meijden PEJ, Ten Cate H. The coagulation system in atherothrombosis: implications for new therapeutic strategies[J]. Res Pract Thromb Haemost, 2018,2: 188-198.
[15] Colao A, Grasso LFS, Di Somma C, et al. Acromegaly and Heart Failure[J]. Heart Fail Clin, 2019,15: 399-408.
[16] Mizera L, Elbaum M, Daroszewski J, et al. Cardiovascular complications of acromegaly[J]. Acta Endocrinologica-Bucharest, 2018,14: 365-374.
[17] Alakbarzade V, Taylor A, Scully M, et al. Utility of current thrombophilia screening in young patients with stroke and TIA[J]. Stroke Vasc Neurol, 2018,3: 231-236.
[18] Undas A, Natorska J. Improving fibrinolysis in venous thromboembolism: impact of fibrin structure[J]. Expert Rev Hematol, 2019,12: 597-607.
[19] Cwikiel J, Seljeflot I, Berge E, et al. Pro-coagulant activity during exercise testing in patients with coronary artery disease[J]. Thromb J, 2017,15: 3.
[20] Jung RG, Motazedian P, Ramirez FD, et al. Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis[J]. Thromb J, 2018,16: 12.
[21] Erdogan M, Ozbek M, Akbal E, et al. Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in acromegaly patients in remission[J]. Turk J Med Sci, 2019,49: 1381-1385.
[22] Dai H, Shi J, He Q, et al. Dose-response relationship between thrombin-activatable fibrinolysis Inhibitor (TAFI) and stroke: a Chinese case-control study[J]. Med Sci Monit, 2017,23: 4376-4381.
[23] Arpaci D, Kuzu F, Unal M, et al. Assessment of mean platelet volume and its effect on disease control in patients with acromegaly[J]. Clin Lab, 2016,62: 2167-2171.
[24] Ucler R, Aslan M, Atmaca M, et al. The effect of disease control on mean platelet volume and red blood cell distribution in patients with acromegaly[J]. Int J Clin Exp Med, 2015,8: 6060-6066.